Foley Advises Motorpharma in Licensing Agreement for Myosin-2 Inhibitor

19 November 2021 Media Contact: Jen Dilworth News

Foley & Lardner LLP served as legal advisor to Budapest-based drug development startup Motorpharma, Ltd. (“Motorpharma”), a spin-off company of Eötvös Loránd University, in a licensing agreement for its myosin-2 inhibitor with Motric Bio, a portfolio company of biotech investment firm Aditum Bio.

Following the successful in-licensing of the myosin-2 inhibitor, Motric Bio was formed by Aditum Bio and Motorpharma to develop a new therapy for spasticity associated with neurological injuries and disease. Motorpharma’s molecule, which is the result of 20 years of research, has shown selective inhibition to fast skeletal muscle, reducing the number of neurological and cardiovascular side effects typically seen with current treatments.

Motorpharma was established by Professor András Málnási-Csizmadia. Its Málnási-laboratory has been one of the flagships of actin-myosin motor protein research for the last two decades.

The Foley deal team was led by Partner Gabor Garai, chair of the firm’s Private Equity & Venture Capital Practice and co-chair of the Life Sciences team.

Related Services

Insights